Skip to content

Ali Ahmadzade

2 papers in the library · 11 citations · publishing 2022

Papers

Ketamine for suicidality: An umbrella review

British Journal of Clinical Pharmacology April 22, 2022 Ahmad Shamabadi, Ali Ahmadzade, Alireza Hasanzadeh 11 citations

A systematic review of systematic reviews found preliminary evidence that ketamine may reduce suicidal thoughts in the short term, but long-term effects remain unknown. Most of the 27 reviewed studies reported positive effects, though only four showed mixed or negative results. Among nine reviews of esketamine, only five found significant benefit. Common side effects included a temporary rise in pulse and blood pressure, dissociation, confusion, blurred vision, nausea, and vertigo, mostly mild. Over two-thirds of the included reviews were rated low or critically low quality, highlighting the need for further research.

Ketamine and Other Glutamate Receptor Modulating Agents for Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials.

Iranian journal of psychiatry July 1, 2022 Ahmad Shamabadi, Ali Ahmadzade, Ali Aqamolaei et al.

A systematic review of 38 randomized controlled trials found compelling evidence that ketamine (with or without electroconvulsive therapy, intravenous or other forms), nitrous oxide, amantadine, and rislenemdaz (MK-0657) are effective for treatment-resistant depression, though results for the latter three were each based on a single study. Lithium, lanicemine, D-cycloserine, and decoglurant showed mixed results, while riluzole and 7-chlorokynurenic acid were mostly comparable to placebo. High heterogeneity among trials prevented determining the difference between statistical and clinical significance. Ketamine appears efficacious, but optimal dosage, duration, and intervals remain unclear.